Red Light Holland submits a new patent application for its microdosing kits.
Exploring the companies and themes that make up this emerging and exciting new sector
New York Lawmakers Discuss Competing Psychedelics Reform Bills Ahead Of Key Deadline
With just a month left before the end of New York’s legislative session, lawmakers sponsoring differing psychedelics reform legislation recently participated in a discussion on the path forward for psilocybin in the Empire State.
Wesana Announces Singular Focus on Drug Development Prompting a Strategic Review of its Clinics and Other Care Delivery Assets
Wesana announces a strategic review of its assets and a decision to focus on drug development.
Optimi Health Granted Amendment To Controlled Substances Dealer’s Licence
Optimi Health announces receiving amendment to Health Canada's Dealer's License that will allow expand cultivation and research use of psilocybin and psilocin.
Ketamine Wellness Centers (KWC) Introduces NAD+ Infusion Therapy
Delic Holdings announces a new health & wellness therapy offered through its Ketamine Wellness Centers mental health clinics.
Awakn Life Sciences Reports Fiscal Fourth Quarter and Fiscal Year January 31, 2022, Results
Awakn Life Sciences reports fourth quarter and full-year results for its fiscal year ending January 31, 2022. Annual revenues of CAD$236,037.
Incannex Completes Loyalty Option Program to Raise A$23.6M; Current Cash at Bank is Approximately A$40.0M
Incannex Healthcare announces a "shareholder loyalty option" to raise A$23.6 million (US$16.5 million). For every two shares purchased, investors will receive a "piggyback option".
Optimi Health Opens Canada’s Largest GMP-Grade Licensed Psilocybin Cultivation Facility
Optimi Health announces the opening of Canada's largest GMP-grade psilocybin cultivation operating, including a 10,000 square foot production facility.
Is The Psychedelic Drug Industry Entering A New Phase?
Several major new deals in the psychedelics industry already in 2022 suggest that the industry could be moving on to its next phase of evolution.
Field Trip Health Ltd. Announces Intention to Separate the Field Trip Discovery and Field Trip Health Divisions Into Two Independent Public Companies
Field Trip announces its corporate decision to separate Field Trip Health and Field Trip Discovery into separate companies.
TRYP THERAPEUTICS DOSES FIRST PATIENT IN PHASE II PSILOCYBIN-ASSISTED THERAPY CLINICAL TRIAL
Tryp Therapeutics announces initial patient enrollment in its Phase II clinical trial of a psilocybin-based compound (TRP-8802) for Binge Eating Disorder.
Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets
Private psychedelics company, Terran Biosciences announces a drug development partnership with Sanofi S.A. for the development and commercialization of two late-stage CNS drugs.